Live
- Centre completes auction of 3 coal blocks, to yield annual revenue of Rs 2,710 crore
- Ullal Woman Files Complaint Against Husband Over Instant Talaq and Abuse
- Analysis: Russia's Nuclear-Capable Missile Marks Shift from Cold War Deterrence Doctrine
- OpenAI Plans In-House Browser "SearchGPT" to Compete with Google Chrome
- MP: Sanatan Hindu Ekta march gets support from BJP & Congress
- Trinamool to hold crucial Working Committee meeting on Monday, organisational reshuffle on agenda
- Who is Breon Peace? The US Attorney Behind the Indictment of Gautam Adani
- Quick commerce workforce expansion to surge by 60 pc in India
- Omar Abdullah to embark on Umrah visit to Saudi Arabia on Nov 24
- Hyderabad Population 2024: 1.6 Crore People and 85 Lakh Vehicles Under HYDRAA's Jurisdiction
Probably we will have a very happy New Year: DCGI
Probably we will have a very happy New Year: DCGI
India is likely to have a Covid-19 vaccine in the New Year, Drug Controller General of India V G Somani hinted on Thursday
New Delhi: India is likely to have a Covid-19 vaccine in the New Year, Drug Controller General of India V G Somani hinted on Thursday. Speaking at a webinar, Somani said the most important thing is that the industry and research organisations have stood the test of time.
Somani said vaccine candidates have got the funding and also talked about the efforts made by the Department of Biotechnology. "...and probably we will have a very happy New Year with something in hand. That's what I can hint at," Somnai said.
The Serum Institute of India, Bharat Biotech and Pfizer have applied to the DCGI seeking emergency use authorisation for their Covid-19 vaccine candidates and are awaiting approval. Somani said the approval process was fast-tracked in view of the pandemic by quickly processing all applications, allowing parallel phase 1 and 2 trials without waiting for complete data.
"There has been no compromise on the safety or efficacy of the data. The only thing is that the regulator has accepted partial data," he said. An expert panel in the Central Drugs Standard Control Organisation (CDSCO) that met on Wednesday to consider emergency use authorisation applications by SII for the Oxford Covid-19 vaccine and Bharat Biotech's 'Covaxin' will reconvene on January 1 to further deliberate on the matter.
The Subject Expert Committee (SEC) on Covid-19 on Wednesday deliberated and analysed the additional data and information submitted by the Serum Institute of India (SII) and Bharat Biotech.
